Gene expression analysis during progression of malignant meningioma compared to benign meningioma
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Gene expression analysis during progression of malignant meningioma compared to benign meningioma. / Maier, Andrea D; Meddis, Alessandra; Mirian, Christian; Haslund-Vinding, Jeppe; Bartek, Jiri; Krog, Sebastian M; Nguyen, Thi Uyen Phuong; Areškevičiūtė, Aušrinė; Melchior, Linea C; Heegaard, Steffen; Kristensen, Bjarne W; Munch, Tina N; Fugleholm, Kåre; Ziebell, Morten; Raleigh, David R; Poulsen, Frantz R; Gerds, Thomas A; Litman, Thomas; Scheie, David; Mathiesen, Tiit.
In: Journal of Neurosurgery, Vol. 138, No. 5, 2023, p. 1-11.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Gene expression analysis during progression of malignant meningioma compared to benign meningioma
AU - Maier, Andrea D
AU - Meddis, Alessandra
AU - Mirian, Christian
AU - Haslund-Vinding, Jeppe
AU - Bartek, Jiri
AU - Krog, Sebastian M
AU - Nguyen, Thi Uyen Phuong
AU - Areškevičiūtė, Aušrinė
AU - Melchior, Linea C
AU - Heegaard, Steffen
AU - Kristensen, Bjarne W
AU - Munch, Tina N
AU - Fugleholm, Kåre
AU - Ziebell, Morten
AU - Raleigh, David R
AU - Poulsen, Frantz R
AU - Gerds, Thomas A
AU - Litman, Thomas
AU - Scheie, David
AU - Mathiesen, Tiit
PY - 2023
Y1 - 2023
N2 - OBJECTIVE: Meningioma is the most common primary intracranial neoplasm. Only 1%-3% of meningiomas are malignant according to the 2016 WHO criteria (WHO grade III). High-grade meningiomas present specific gene expression signatures indicating aggressive growth or recurrence. However, changes in gene expression and in neuroinflammatory gene expression signatures in WHO grade III meningiomas and during progression from WHO grade I or II to grade III are unknown.METHODS: The authors used a NanoString targeted gene expression panel with focus on 787 genes relevant in meningioma pathology and neuroinflammatory pathways to investigate patients with grade III meningiomas treated at Rigshospitalet from 2000 to 2020 (n = 51). A temporal dimension was added to the investigation by including samples from patients' earlier grade I and II meningiomas and grade III recurrences (n = 139 meningiomas). The authors investigated changes in neuroinflammatory gene expression signatures in 1) grade I meningiomas that later transformed into grade III meningiomas, and 2) grade III meningiomas compared with nonrecurrent grade I meningiomas.RESULTS: The authors' data indicate that FOXM1, TOP2A, BIRC5, and MYBL2 were enriched and the HOTAIR regulatory pathway was enriched in grade III meningiomas compared with nonrecurrent grade I meningiomas. They discovered a separation of malignant and benign meningiomas based only on genes involved in microglia regulation with enrichment of P2RY12 in grade I compared with grade III meningiomas. Interestingly, FOXM1 was upregulated in premalignant grade I meningioma years before the grade III transformation.CONCLUSIONS: The authors found gene expression changes in low-grade meningiomas that predated histological transformation to grade III meningiomas. Neuroinflammation genes distinguished grade III from grade I meningiomas.
AB - OBJECTIVE: Meningioma is the most common primary intracranial neoplasm. Only 1%-3% of meningiomas are malignant according to the 2016 WHO criteria (WHO grade III). High-grade meningiomas present specific gene expression signatures indicating aggressive growth or recurrence. However, changes in gene expression and in neuroinflammatory gene expression signatures in WHO grade III meningiomas and during progression from WHO grade I or II to grade III are unknown.METHODS: The authors used a NanoString targeted gene expression panel with focus on 787 genes relevant in meningioma pathology and neuroinflammatory pathways to investigate patients with grade III meningiomas treated at Rigshospitalet from 2000 to 2020 (n = 51). A temporal dimension was added to the investigation by including samples from patients' earlier grade I and II meningiomas and grade III recurrences (n = 139 meningiomas). The authors investigated changes in neuroinflammatory gene expression signatures in 1) grade I meningiomas that later transformed into grade III meningiomas, and 2) grade III meningiomas compared with nonrecurrent grade I meningiomas.RESULTS: The authors' data indicate that FOXM1, TOP2A, BIRC5, and MYBL2 were enriched and the HOTAIR regulatory pathway was enriched in grade III meningiomas compared with nonrecurrent grade I meningiomas. They discovered a separation of malignant and benign meningiomas based only on genes involved in microglia regulation with enrichment of P2RY12 in grade I compared with grade III meningiomas. Interestingly, FOXM1 was upregulated in premalignant grade I meningioma years before the grade III transformation.CONCLUSIONS: The authors found gene expression changes in low-grade meningiomas that predated histological transformation to grade III meningiomas. Neuroinflammation genes distinguished grade III from grade I meningiomas.
U2 - 10.3171/2022.7.JNS22585
DO - 10.3171/2022.7.JNS22585
M3 - Journal article
C2 - 36115056
VL - 138
SP - 1
EP - 11
JO - Journal of Neurosurgery
JF - Journal of Neurosurgery
SN - 0022-3085
IS - 5
ER -
ID: 345318563